AMCP's volunteers are vital players in propelling our mission forward. In this installment of the AMCP Volunteer Spotlight, we are featuring Brenden O'Hara, RPh, BCACP, Carolinas AMCP President, Diplomat, and Professional Practice Committee member.
On Dec. 21, the Department of Health and Human Services released a proposed rule titled "Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2024." On Jan. 30, AMCP submitted comments which oppose two issues from the proposed rule; continuing formulary tier limitations for standardized plan options and new limits on the number of non-standardized plan options that issues may offer through the federal Marketplace.
On Jan. 27, AMCP, along with 76 other healthcare organizations, signed on to a consensus statement on health equity. In the statement, signatories recognize health inequity as a complex issue and reaffirm their commitment to take action within their organizations to reduce health inequities for the broader population.
In the world of health care innovation, speed matters. But when it comes to developing and deploying cutting-edge treatments and therapeutics safely, a cautious and methodical approach is vital as well. Safety matters as much as speed, but faster doesn’t always mean riskier. In her latest blog, AMCP CEO Susan Cantrell discusses the history of the Pre-approval Information Exchange (PIE) Act and how it will help patients.
January 2023 Legislative & Regulatory Briefing: The PIE Act of 2022 Becomes Law; Member Benefit! Stay Up to Date on IRA Guidance with Regulatory NewsBREAKs; Media Coverage Captures Its Own Piece of the PIE; Reimbursement for PDTs Could Increase Access to Emerging Treatments; Registration is Now Open for AMCP 2023 in San Antonio.
Hemophilia, sickle cell disease (SCD), and beta-thalassemia (β thal) are inherited blood disorders likely to see multiple significant novel therapies approved in the near future, including the possibility for partial or complete cures with gene therapies. To understand the appropriate and cost-effective use of treatments for inherited blood disorders, AMCP convened an expert panel of managed care stakeholders in October 2022.
Chronic lymphocytic leukemia (CLL) is characterized by a progressive accumulation of leukemia cells in the peripheral blood, bone marrow, and lymphoid tissues. Bruton tyrosine kinase inhibitors (BTKis) are a preferred treatment of patients with CLL. In September 2022, AMCP convened an expert panel of managed care stakeholders to better understand the clinical dynamics of treatment choice in patients with CLL and the key management considerations in CLL with a focus on BTKis.